ArticlePloS one2026
Spatial and temporal distribution of thyroid cancer incidence in China: An ecological study based on a national registry.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to analyze the incidence rate of thyroid cancer in China to elucidate its spatiotemporal distribution and to provide an evidence-based foundation for prevention and control strategies. Thyroid cancer incidence data from 2005 to 2018 were obtained from the China Cancer Registry Annual Reports (2008-2021). The Joinpoint regression model was used to describe the time trend, the age-period-cohort model was employed to analyze the effects of age, period and cohort on the thyroid cancer incidence, and spatial autocorrelation was used to analyze its spatial distribution. Results showed China's age-standardized incidence rate (ASIR) of thyroid cancer from 2005 to 2018 was 8.69 (95% CI: 8.55, 8.83) per 100,000, exhibiting an upward trend with an average annual percent change (AAPC) of 10.7% (95% CI: 9.5%, 11.9%). The ASIR was higher in urban than in rural areas, though its growth rate was lower than in rural areas; similarly, it was higher in females than males but grew slower than in males. Nationally, incidence risk initially increased and then declined with advancing age, while period effects showed an upward trend and cohort effects a downward trend. Spatial autocorrelation revealed clustered incidence patterns, with northeastern China exhibiting a high-high clustering. Although this study is limited by the lack of pathological classification, the delay in the latest data, and potential biases from the increasing number of surveillance sites, these findings also suggest that the national thyroid cancer surveillance system should be further strengthened, a registration system for high-risk populations should be established, and greater investment should be allocated to etiological research, such as through measures like controlling weight and regulating radiation to reduce the risk of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.